The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients

Trial Profile

The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs Eslicarbazepine acetate (Primary) ; Phenytoin
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Bial
  • Most Recent Events

    • 22 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top